The IDH1 Antibody (PAC027485) is a polyclonal antibody designed for research involving the IDH1 enzyme, which plays a crucial role in cellular metabolism and has been implicated in various diseases, including cancer. This antibody, raised in rabbits, is highly specific to human samples and has been validated for use in Western blot and immunohistochemistry applications.IDH1 is a key enzyme in the citric acid cycle and is frequently mutated in various cancers, leading to abnormal production of the metabolite 2-hydroxyglutarate.
Understanding the role of IDH1 in cancer development and progression is essential for the development of targeted therapies and diagnostic tools.The IDH1 Antibody (PAC027485) enables researchers to detect and analyze the expression of IDH1 in different cell types and tissue samples, making it a valuable tool for studies in oncology and metabolic diseases. By targeting and inhibiting the activity of mutated IDH1, researchers aim to develop novel treatments that specifically target cancer cells harboring these mutations.
IDH1: an oxidoreductase that catalyzes the third step of the TCA cycle: the oxidative decarboxylation of isocitrate, consuming NADP(+), and producing alpha-ketoglutarate (alpha-KG) and CO2. Alpha-KG is an activator the dioxygenases that hydroxylate the transcription factor HIF and lead to its degradation by VHL. Since HIF turns on oncogenic pathways, IDH1 has apparent tumor suppressor activity. Homo-dimerization is required for activity. Each subunit binds 1 magnesium or manganese ion. IDH1 is located in the cytosol and peroxisomes. Somatic mutations affecting arginine 132 (R132) are found in 80% of grade II?III gliomas and secondary glioblastomas in humans, and cause disease in a tissue-specific fashion. Only a single copy of the gene has been found to be mutated in tumours. Mutations of R132 to H, C, S, G, V, or L have been reported to be neomorphic, abolishing the conversion of isocitrate to alpha-KG. Instead, alpha-KG is converted to R(-)-2-hydroxyglutarate (2HG). Elevated levels of 2HG correlate with an elevated risk of malignant brain tumors. Neomorphic mutations in IDH1 and IDH2 convert alpha-KG to 2-hydroxyglutarate (2-HG) occur in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML). Protein type: Carbohydrate Metabolism - citrate (TCA) cycle; EC 1.1.1.42; Other Amino Acids Metabolism - glutathione; OxidoreductaseChromosomal Location of Human Ortholog: 1 C2|1 32.91 cMCellular Component: cytoplasm; cytosol; mitochondrion; peroxisomeMolecular Function: (R)-2-hydroxyglutarate dehydrogenase activity; cadherin binding; isocitrate dehydrogenase (NADP+) activity; isocitrate dehydrogenase activity; magnesium ion binding; NADP binding; protein homodimerization activity; receptor bindingBiological Process: 2-oxoglutarate metabolic process; glutathione metabolic process; isocitrate metabolic process; response to organic cyclic substance; response to oxidative stress; response to steroid hormone stimulus